Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1309-1318

  Casado, José A ^a   Río, Paula ^a   Marco, Esther ^b   García Hernández, Verónica ^b   Domingo, Alberto ^b   Pérez, Laura ^a,c   Tercero, Juan Carlos ^c   Vaquero, Juan José ^b   Albella, Beatriz ^a   Gago, Federico ^b   Bueren, Juan A ^a,d  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c PHARMAMAR S A   (Spain)

^d CIEMAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP F PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; HISTONE H2AX; MITOMYCIN C; RAD51 PROTEIN; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; DNA; FANCONI ANEMIA PROTEIN; MITOMYCIN; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA HELIX; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DNA BINDING; DRUG RESPONSE; FANCONI ANEMIA; FLUORESCENCE ANALYSIS; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THERMOSTABILITY; CELL CYCLE; DOSE RESPONSE; GENETICS; METABOLISM; TIME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; DIOXOLES; DNA; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; MITOMYCIN; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 49849096707     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2432     Document Type: Article

References (50)

1. Schoffski P, Wolter P, Clement P, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007;3:381-92.
2. Gago F, Hurley LH. Devising a structural basis for the potent cytotoxic effects of ecteinascidin 743. In: Demeunynck M, Bailly C, Wilson WD, editors. Small molecule DNA and RNA binders: from synthesis to nucleic acid complexes. Weinheim (Germany): Wiley-VCH; 2002. p. 643-75.
3. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377-81.
4. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
5. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
6. Beljanski V, Marzilli LG, Doetsch PW. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA crosslinking drugs. Mol Pharmacol 2004;65:1496-506.
7. Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res 2004;10:5604-13.
8. Lee YJ, Park SJ, Ciccone SL, Kim CR, Lee SH. An in vivo analysis of MMC-induced DNA damage and its repair. Carcinogenesis 2006;27:446-53.
9. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8.
10. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
11. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
12. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 2005;70:59-69.
13. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155-62.
14. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003;4:435-45.
15. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007;104:13062-7.
16. Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001;307:1235-45.
17. Guirouilh-Barbat J, Sedelnikova OA, Bonner WM, Pommier Y. Ecteinascidin-induced DNA double strand breaks: a link between histone γ-H2AX, transcription-coupled nucleotide excision repair and Mre11 endonuclease. AACR Annual Meeting, Washington, DC, 2006; poster 4642.
18. Casado JA, Albella B, Río P, et al. Generation of DNA double-strand breaks during trabectedin (Yondelis) DNA damage measured through induction of γH2AX. AACR Annual Meeting, Los Angeles, CA, 2007; poster 1965.
19. Marco E, Garcia-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimics zinc finger-induced DNA structural distortions. J Med Chem 2002;45:871-80.
20. Marco E, Gago F. DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands. Mol Pharmacol 2005;68:1559-67.
21. Iyer VN, Szybalski W. A molecular mechanism of mitomycin action: linking of complementary DNA strands. Proc Natl Acad Sci U S A 1963;50:355-62.
22. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-87.
23. Negri A, Marco E, Garcia-Hernandez V, et al. Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptide. J Med Chem 2007;50:3322-33.
24. Andreassen PR, Ho GP, D'Andrea AD. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006;27:883-92.
25. Taniguchi T, D'Andrea AD. The molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107:4223-33.
26. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9:568-74.
27. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 2004;64:2994-7.
28. van der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004;165:651-7.
29. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11:7508-15.
30. Thompson E, Dragovic RL, Stephenson SA, Eccles DM, Campbell IG, Dobrovic A. A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer. BMC Cancer 2005;5:43.
31. Casado JA, Callen E, Jacome A, et al. A comprehensive strategy for the subtyping of Fanconi anemia patients: conclusions from the Spanish Fanconi Anemia research network. J Med Genet 2007;44:241-9.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Huang X, Darzynkiewicz Z. Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. Methods Mol Biol 2006;314:73-80.
34. Marco E, David-Cordonnier MH, Bailly C, Cuevas C, Gago F. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J Med Chem 2006;49:6925-9.
35. David-Cordonnier MH, Gajate C, Olmea O, et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005;12:1201-10.
36. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8:1033-49.
37. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997;76:73-87.
38. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-42.
39. Svejstrup JQ. Mechanisms of transcription-coupled DNA repair. Nat Rev Mol Cell Biol 2002;3:21-9.
40. D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist 2002;7:210-6.
41. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902.
42. Huang H, Woo J, Alley SC, Hopkins PB. DNA-DNA interstrand crosslinking by cis-diamminedichloroplatinum(II): N7(dG)-to-N7(dG) cross-linking at 5′-d(GC) in synthetic oligonucleotides. Bioorg Med Chem 1995;3:659-69.
43. Larminat F, Zhen W, Bohr VA. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. J Biol Chem 1993;268:2649-54.
44. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells: transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial-mediated apoptosis. J Biol Chem 2002;26:26.
45. Mladenov E, Tsaneva I, Anachkova B. Activation of the Sphase DNA damage checkpoint by mitomycin C. J Cell Physiol 2007;211:468-76.
46. Howlett NG, Taniguchi T, Olson S, et al. Biallelic Inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
47. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007;8:735-48.
48. Sasaki MS. Is Fanconi's anaemia defective in a process essential to the repair of DNA cross links? Nature 1975;257:501-3.
49. Paz MM, Das A, Palom Y, He QY, Tomasz M. Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem 2001;44:2834-42.
50. Penketh PG, Hodnick WF, Belcourt MF, Shyam K, Sherman DH, Sartorelli AC. Inhibition of DNA cross-linking by mitomycin C by peroxidase-mediated oxidation of mitomycin C hydroquinone. J Biol Chem 2001;276:34445-52.